Genitourinary Cancers | Specialty

Dr. Figlin on Novel Combinations in Kidney Cancer Treatment

March 2nd 2020

Robert A. Figlin, MD, discusses novel combinations in the treatment of patients with kidney cancer.

Dr. McGregor on Combos With Nivolumab, Cabozantinib, and Sunitinib in RCC

February 29th 2020

Bradley McGregor, MD, discusses combination therapies with nivolumab, cabozantinib, and sunitinib in renal cell carcinoma.

Dr. Powles on the Mission of the Uromigos Twitter Group

February 29th 2020

Thomas Powles, MD, MBBS, MRCP, discusses the mission and goals for the Uromigos Twitter group.

First-in-Class ADC Expands Portfolio of Precision Therapies in Bladder Cancer

February 28th 2020

Bradley McGregor, MD, discusses enfortumab vedotin-ejfv’s path to approval and its future potential in bladder cancer.

Dr. Joshi on Durvalumab/RT Combo in Locally Advanced Urothelial Cancer

February 28th 2020

Monika Joshi, MD, discusses durvalumab (Imfinzi) and radiation therapy (DUART) in locally advanced urothelial cancer of the bladder.

Despite Setback, Expert Sees Novel Immunotherapy Combos on Horizon in mRCC

February 21st 2020

Martin H. Voss, MD, discusses the phase I/II trial evaluating MEDI0680 plus durvalumab in metastatic renal cell carcinoma and what similar research efforts lie ahead.

FDA Grants Breakthrough Designation to Frontline Enfortumab Vedotin/Pembrolizumab in Bladder Cancer

February 20th 2020

The FDA has granted a breakthrough therapy designation to the combination of enfortumab vedotin-ejfv and pembrolizumab as a first-line treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy.

Dr. Bakouny on the Role of Cytoreductive Nephrectomy in mRCC

February 19th 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Dr. Vaishampayan on Systemic Therapy Followed by Cytoreductive Nephrectomy in mRCC

February 18th 2020

Ulka Vaishampayan, MD, discusses the considerations when giving patients with metastatic renal cell carcinoma systemic therapy followed by cytoreductive nephrectomy.

Breaking Ground in GU Cancers

February 17th 2020

Daniel P. Petrylak, MD, discusses important new developments in bladder and prostate cancer.

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15th 2020

Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

Dr. Alva on the Shift Toward Combination Therapy in mRCC

February 15th 2020

Ajjai Shivaram Alva, MBBS, discusses the shift toward combination therapy versus monotherapy in metastatic renal cell carcinoma.

Dr. Figlin on the Evolving Treatment Landscape of Renal Cell Carcinoma

February 15th 2020

Robert A. Figlin, MD, discusses the evolving treatment landscape of renal cell carcinoma (RCC).

ASCO GU 2020: Dr. Rini Highlights Key Research Efforts in Kidney Cancer

February 14th 2020

ASCO GU 2020: Dr. Petrylak Discusses Exciting Prostate Cancer and Bladder Cancer Data

February 14th 2020

ASCO GU 2020: Dr. Taplin Highlights Ongoing Research in Prostate Cancer

February 14th 2020

ASCO GU 2020: Dr. Sonpavde Highlights Advancements in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Galsky Provides Insight on Potentially Practice-Changing Studies in Bladder Cancer

February 14th 2020

ASCO GU 2020: Dr. Albiges Recounts Exciting Research in RCC

February 14th 2020

OncLive News Network On Location: GU 2020 Day 3

February 14th 2020